That's a fair point Sewell64 although you should remember that ADAPT products have also been implanted in over 20 000+ patients worldwide and have a history of being calcification free for 10+ years.
No competitor can claim the same.Whilst I don't think anyone here is expecting the DurAVR to take 100% market share immediately with the best science and the best doctors supporting us I believe that the DurAVR should, over time, take considerable market share away from both Edwards and Medtronic as any patient, when consulted with the facts (as they stand now,) would likely choose us over a competitor, (performance aside, I can't imagine anyone choosing a valve which in 5-7 years will have to be replaced over a valve which will likely not have to be replaced.)
AVR Price at posting:
$25.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)